SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Seeking Alpha / 13 hours ago 1 Views
SAB to host webinar event to discuss Phase 1 clinical trial topline results
Seeking Alpha / 13 hours ago 1 Views
Comments